PDCD1 and metastatic melanoma: A first in-human phase 1/2 trial of TALEN-mediated PD-1–inactivated TILs (PDCD-1 knockout TILs) is currently ongoing with a plan to enroll 53 patients with metastatic melanoma and NSCLC to assess the safety and ORR [73].